Fig. 1From: Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)AML progression by age group in lenalidomide-treated patients (a) or after treatment failure (b). There are 52 patients in the <65 years age group, but 1 patient died on day 0 and has been excluded from the analyses. AML acute myeloid leukemiaBack to article page